228 related articles for article (PubMed ID: 30563890)
1. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
[TBL] [Abstract][Full Text] [Related]
2. WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.
Wend P; Runke S; Wend K; Anchondo B; Yesayan M; Jardon M; Hardie N; Loddenkemper C; Ulasov I; Lesniak MS; Wolsky R; Bentolila LA; Grant SG; Elashoff D; Lehr S; Latimer JJ; Bose S; Sattar H; Krum SA; Miranda-Carboni GA
EMBO Mol Med; 2013 Feb; 5(2):264-79. PubMed ID: 23307470
[TBL] [Abstract][Full Text] [Related]
3. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F; Moussa N; Helmy MW; Haroun M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling.
Fatima I; El-Ayachi I; Playa HC; Alva-Ornelas JA; Khalid AB; Kuenzinger WL; Wend P; Pence JC; Brakefield L; Krutilina RI; Johnson DL; O'Regan RM; Seewaldt V; Seagroves TN; Krum SA; Miranda-Carboni GA
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861131
[TBL] [Abstract][Full Text] [Related]
7. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
8. HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway.
Xu J; Fang X; Long L; Wang S; Qian S; Lyu J
Cancer Biol Ther; 2021 Jan; 22(1):5-11. PubMed ID: 33307962
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
10. YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer.
Quinn HM; Vogel R; Popp O; Mertins P; Lan L; Messerschmidt C; Landshammer A; Lisek K; Château-Joubert S; Marangoni E; Koren E; Fuchs Y; Birchmeier W
Cancer Res; 2021 Apr; 81(8):2116-2127. PubMed ID: 33574090
[TBL] [Abstract][Full Text] [Related]
11. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
13. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 12p Amplification in Triple-Negative/
Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Sole A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monso MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E
Cancer Res; 2019 Aug; 79(16):4258-4270. PubMed ID: 31213465
[TBL] [Abstract][Full Text] [Related]
15. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
[TBL] [Abstract][Full Text] [Related]
16. PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.
Cox OT; Edmunds SJ; Simon-Keller K; Li B; Moran B; Buckley NE; Bustamante-Garrido M; Healy N; O'Flanagan CH; Gallagher WM; Kennedy RD; Bernards R; Caldas C; Chin SF; Marx A; O'Connor R
Cancer Res; 2019 May; 79(10):2619-2633. PubMed ID: 30885980
[TBL] [Abstract][Full Text] [Related]
17. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
18. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
19. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
20. Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.
Mei H; Wu H; Yang J; Zhou B; Wang A; Hu C; Qi S; Jiang Z; Zou F; Wang B; Liu F; Chen Y; Wang W; Liu J; Liu Q
Signal Transduct Target Ther; 2023 Jan; 8(1):18. PubMed ID: 36642705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
